Subscribe to RSS
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/s-0041-1739542
Use of Denosumab in Aneurysmatic Bone Cyst: Literature Review
Article in several languages: español | English![](https://www.thieme-connect.de/media/10.1055-s-00033425/202201/lookinside/thumbnails/10-1055-s-0041-1739542_2000059_en-1.jpg)
Abstract
Introduction Aneurysmal Bone Cysts (ABCs) are locally-aggressive benign tumors with relevant potential for recurrence, representing approximately 1% of all bone tumors. Multiple treatments are described for them, such as: intralesional excision, selective arterial embolization, injection of sclerosing agents, and radiation. These treatments have a variable efficacy rate, can reach 20% and may be associated with serious comorbidities such as functional loss of the limb.
Objective To perform an integrative review of the literature on the use of denosumab in the treatment of ABCs, describing the epidemiological profile, the dosage used, and the complications.
Methodology Articles published in the past five years were retrieved from the PubMed database. The information collected from the cases reported was age, gender, tumor location, the performance of surgery before and/or after the denosumab treatment, the dose used, the complications, and recurrence.
Results We analyzed 7 articles, 4 case reports and 3 case series, written in English, and published from 2014 to 2019. Most patients were female, with an average age of 14 years, with the tumor located in the spine.
Conclusion The use of denosumab in the treatment of ABCs yielded good results, with low rates of recurrence and complications. However, further studies are needed to define a treatment protocol.
Palabras Clave
quiste óseo aneurismático (MeSH ID: D017824) - denosumab (ID MeSH: 000069448) - revisión de la literatura (MeSH ID: D003211)Publication History
Received: 15 October 2020
Accepted: 06 August 2021
Article published online:
20 January 2022
© 2022. Sociedad Chilena de Ortopedia y Traumatologia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commecial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
-
Referencias
- 1 Dürr HR, Grahneis F, Baur-Melnyk A. et al. Aneurysmal bone cyst: results of an off label treatment with Denosumab. BMC Musculoskelet Disord 2019; 20 (01) 456
- 2 Raux S, Bouhamama A, Gaspar N. et al. Denosumab for treating aneurysmal bone cysts in children. Orthop Traumatol Surg Res 2019; 105 (06) 1181-1185
- 3 Kurucu N, Akyuz C, Ergen FB. et al. Denosumab treatment in aneurysmal bone cyst: Evaluation of nine cases. Pediatr Blood Cancer 2018; 65 (04) 1-7
- 4 Fontenot PB, Jesurajan J, Bui M, Reed D, Binitie O. Recurrent Aneurysmal Bone Cyst of the Distal Fibula Treated with Denosumab and Curettage. Case Rep Oncol Med 2018; 2018: 1574343
- 5 Kulkarni AG, Patel A. Denosumab: A potential new treatment option for recurrent Aneurysmal Bone Cyst of the spine. SICOT J 2019; 5: 10
- 6 Martin-Broto J, Cleeland CS, Glare PA. et al. Effects of denosumab on pain and analgesic use in giant cell tumor of bone: interim results from a phase II study. Acta Oncol 2014; 53 (09) 1173-1179
- 7 Ntalos D, Priemel M, Schlickewei C, Thiesen DM, Rueger JM, Spiro AS. Therapeutic Management of a Substantial Pelvic Aneurysmatic Bone Cyst Including the Off-Label Use of Denosumab in a 35-Year-Old Female Patient. Case Rep Orthop 2017; 2017: 9125493
- 8 Lange T, Stehling C, Fröhlich B, Klingenhöfer M, Kunkel P, Schneppenheim R. et al. Denosumab: A potential new and innovative treatment option for aneurysmal bone cysts. Eur Spine J 2013; 22 (06) 1417-1422